Brief: Bellus Health Presents Phase 1 Data For Blu-5937

BELLUS Health

21/05/2019 17:17

May 21 (Reuters) - BELLUS Health Inc  BLU.TO :
    * BELLUS HEALTH PRESENTS PHASE 1 DATA FOR BLU-5937, ITS LEAD PRODUCT
CANDIDATE FOR
THE TREATMENT OF REFRACTORY CHRONIC COUGH, AT THE AMERICAN THORACIC SOCIETY
INTERNATIONAL CONFERENCE
    * BELLUS HEALTH - RESULTS CONCLUSIVELY DEMONSTRATE BLU-5937 IS A
DIFFERENTIATED
PRODUCT CANDIDATE THAT HAS LITTLE TO NO IMPACT ON TASTE PERCEPTION
    * BELLUS HEALTH - CLINICAL PHASE 2 STUDY TO ASSESS EFFICACY, SAFETY,
TOLERABILITY
OF BLU-5937 IN CHRONIC COUGH PATIENTS IS EXPECTED TO BEGIN IN MID-2019
    * BELLUS HEALTH -  THERE WERE NO SERIOUS ADVERSE EVENTS REPORTED, NO
SUBJECTS
WITHDREW PREMATURELY DUE TO AN ADVERSE EVENT IN PHASE 1 BLU-5937 TRIAL

Source text for Eikon:  ID:nBw785gCRa 
Further company coverage:  BLU.TO 

 ((Reuters.Briefs@thomsonreuters.com;))